Cell-Easy is a startup based in France. Its most recent tracked round is Series A.
Cell-Easy is a contract development and manufacturing organization (CDMO) that produces ready-to-inject adipose-derived allogeneic stem cell products for preclinical and clinical drug development. Its production is optimized under cGMP conditions and has been inspected by the French ANSM to support scalable, regulatory-compliant supply.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.